Therapeutic Asset Ratings

266 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Vgb-Ex01 Beta Thalassemia	Institute of Hematology & Blood Diseases Hospital, China	N/A	D (30)
Vgb-Ex01 Beta-Thalassemia Major	Institute of Hematology & Blood Diseases Hospital, China	N/A	D (30)
(+)-VINCRISTINE Ph-Like	Institute of Hematology & Blood Diseases Hospital, China	N/A	D (30)
Zanubrutinib Acute Lymphoblastic Leukemia, Adult	Institute of Hematology & Blood Diseases Hospital, China	N/A	D (30)
zs802 Hemophilia A	Institute of Hematology & Blood Diseases Hospital, China	N/A	D (30)
Gecacitinib Acute Lymphoblastic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	N/A	D (28)
kl003 cell Sickle Cell Disease	Institute of Hematology & Blood Diseases Hospital, China	N/A	D (28)
Glofitamab Aggressive B-Cell Non-Hodgkin Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P2	NR (0)
Herombopag Herombopag	Institute of Hematology & Blood Diseases Hospital, China	P2	NR (0)
CLL-1 and CD123 dual-target CAR-T cells Acute Myeloid Leukemia	Institute of Hematology & Blood Diseases Hospital, China	Early P1	NR (0)
Iaso206 Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	Early P1	NR (0)
JK500 cells Childhood Acute Myeloid Leukemia	Institute of Hematology & Blood Diseases Hospital, China	Early P1	NR (0)
qi-019b Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	Early P1	NR (0)
sl4903 autologous t-cell Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	Early P1	NR (0)
cd19x car-t Large B-Cell Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	NR (0)
sb-497115-gr Eltrombopag	Institute of Hematology & Blood Diseases Hospital, China	P2/3	NR (0)

Showing 251 to 266 of 266 assets

PreviousPage 11 of 11Next